Who are Non-immunogenic recombinant staphylokinase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, Tranexamic Acid plus standard of care, Cathflo Activase (Alteplase).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/non-immunogenic-recombinant-staphylokinase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Non-immunogenic recombinant staphylokinase — Competitive Intelligence Brief

Non-immunogenic recombinant staphylokinase (Non-immunogenic recombinant staphylokinase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Plasminogen activator. Area: Cardiovascular.

phase 3 Fibrinolytic agent / Plasminogen activator Plasminogen Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Non-immunogenic recombinant staphylokinase (Non-immunogenic recombinant staphylokinase) — Supergene, LLC. Non-immunogenic recombinant staphylokinase is a fibrinolytic enzyme that directly activates plasminogen to plasmin, dissolving blood clots without triggering immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Non-immunogenic recombinant staphylokinase TARGET	Non-immunogenic recombinant staphylokinase	Supergene, LLC	phase 3	Fibrinolytic agent / Plasminogen activator	Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Cathflo Activase (Alteplase)	Cathflo Activase (Alteplase)	Genentech, Inc.	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Plasminogen activator class)

Supergene, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Non-immunogenic recombinant staphylokinase — Competitive Intelligence Brief. https://druglandscape.com/ci/non-immunogenic-recombinant-staphylokinase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab